Wednesday, July 26, 2017

Text/HTML

PHSANZ Newsletter #2

Issue #2 May 2012

World Symposium of Pulmonary Hypertension

Dear All,

On behalf of the Steering Committee, we are pleased to announce that the “5° World Symposium on Pulmonary Hypertension” will be held in Nice, France on February 27-March 1 2013.

You can find detailed information on the official website www.wsph2013.com.

We would also like to inform you that the online procedures for abstract submission and registration are also available on the same website.

Please, take note of the following deadlines:

June 30th, 2012 – abstract submission

September 30 th, 2012 – abstract acceptance/rejection notification

January 15th, 2013 – online registration (no onsite registration will be accepted)

The Organizing Secretariat I&C is available for any support you may need info@wsph2013.com.

We look forward to seeing you in Nice!

The Organizing Secretariat

Federica Schiassi

Via Andrea Costa, 202/6
40134 Bologna (BO) - ITALY
tel.: +39 - 051.614.4004
fax: +39 - 051.614.2772

***

Treatment Update

PBS Listing of Adcirca™ (tadalafil) from 1st April 2012

Adcirca, a once-daily phosphodiesterase type 5 (PDE-5) inhibitor, is now available on the PBS for the treatment of adults who have primary pulmonary hypertension or pulmonary arterial hypertension (PAH) secondary to connective tissue disease, with disease of WHO Functional Class III severity.

Adcirca is indicated in adults for the treatment of PAH classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. Please refer to the approved Product Information before prescribing.

PBS Information: This product is listed on the PBS as a Section 100 item.
Refer to PBS Schedule for full information.
For details of the PBS listing, please refer to the PBS website: www.pbs.gov.au

Click here to download the full product information sheet

Actelion’s macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension

ALLSCHWIL/BASEL, SWITZERLAND – 30 April 2012 – Actelion (SIX: ATLN) announced today that initial analysis indicates that the pivotal, long-term, event-driven study SERAPHIN with macitentan, a novel dual endothelin receptor antagonist, in 742 patients suffering from pulmonary arterial hypertension (PAH) and treated for up to three and a half years, has met its primary endpoint.

Click here to to download the full media release

***

Contact Us

For more information about the goals and activities of the
Pulmonary Hypertension Society of ANZ please contact:

Geoff Strange
CEO, Pulmonary Hypertension Society ANZ Inc.
PO Box 133, Sans Souci, NSW 2219
Ph 0422 30 8585

geoff.strange@phsanz.com.au

Copyright 2011 by PHSANZ